NeuraLight develops software technologies that extract eye-movement biomarkers from standard webcams and smartphone cameras to assess neurological function. The company’s platform uses computer vision to analyze subtle oculomotor signals without requiring specialized hardware. Its approach focuses on making neurological measurement accessible, scalable, and deployable in remote settings. NeuraLight positions its technology within clinical research and diagnostic development contexts.

The technology analyzes eye movements captured on video to quantify metrics related to attention, motor control, and neurological integrity. AI-driven models process gaze patterns, saccades, and other oculomotor features that are known to correlate with central nervous system function. These biomarkers can be collected repeatedly and remotely, enabling longitudinal assessment with minimal patient burden. The system emphasizes robustness across devices and real-world recording conditions.

NeuraLight targets applications in CNS drug development and neurology diagnostics, where objective and scalable biomarkers are needed to assess disease progression and treatment response. The platform is intended for use in clinical trials and healthcare settings rather than consumer wellness. Its focus reflects growing interest in digital biomarkers that leverage everyday devices to expand access to neurological assessment.